Browse Items · NEOMED Bibliography Database

CEL-1000 - a peptide with adjuvant activity or Th1 immune responses

CEL-1000 (derG, DGQEEKAGVVSTGLIGGG) is a small immunomodulatory peptide which delivers demonstrated protective activity in two infectious disease challenge models (HSV and malaria) and an allogenic tumor vaccine model. CEL-1000 and other activators…

The LEAPS approach to vaccine development

The Ligand Epitope Antigen Presentation System ( L. E. A. P. S. TM) approach to vaccine development utilizes immune peptides to promote the immunogenicity and influence the type of immune response generated towards epitopes in peptides which may be…

Gastrointestinal Infections in the Setting of Natural Disasters

Gastrointestinal illness following natural disasters is a common occurrence and often results from the disruption of potable water supplies. The risk for outbreaks of gastrointestinal illness is higher in developing countries because of fewer…

Tags: 2012, Cholera, Current infectious disease reports, Department of Internal Medicine, Earthquakes, Floods, Gastrointestinal illness, Hepatitis A, Hepatitis E, Hurricanes, Infectious Diseases, Journal Article, NEOMED College of Medicine, Norovirus, Tsunamis, Typhoid fever, Vaccines, Watkins R R

Why Don't We Have a Vaccine Against....? Part 2. Bacteria

Despite the large number of vaccines, this review asks the question: why do we not have vaccines for all infectious diseases? The first of this series discussed basics of vaccine immunology, new approaches, and outlined some of the difficulties and…

Tags: 2016, antibacterial vaccines, attenuated, conjugate vaccines, Disease, Immunology, Infectious Diseases, Infectious Diseases in Clinical Practice, Journal Article, Kuntz A, model, oral vaccines, pertussis, Rosenthal K S, Sikon J, toxoid, Vaccine, Vaccines

Immune peptide enhancement of peptide based vaccines.

Vaccines optimize the presentation of an immunogen to the immune system, oftentimes enhancing or replacing the natural activators of antigen presenting cells in order to promote the delivery and the response of T and B lymphocytes to the immunogen.…

Tags: 2005, Animals, B-Lymphocytes/immunology, Cancer Vaccines/chemistry, Drug Design, Epitopes/chemistry, Frontiers in bioscience : a journal and virtual library, Humans, Immune System/pathology, Peptides/*chemistry, Rosenthal Ken S, Subunit/*chemistry, T-Lymphocytes/immunology, Vaccines

Immunization with a LEAPS heteroconjugate containing a CTL epitope and a peptide from beta-2-microglobulin elicits a protective and DTH response to herpes simplex virus type 1.

A ligand epitope antigen presentation system (LEAPS) heteroconjugate vaccine containing a CTL epitope (H1) from the HSV-1 immediate early protein ICP27 (322-332) and a peptide sequence (J) from beta-2-microglobulin (35-50) elicited protection from…

A L.E.A.P.S. heteroconjugate vaccine containing a T cell epitope from HSV-1 glycoprotein D elicits Th1 responses and protection.

The L.E.A.P.S. heteroconjugate vaccine antigen (JgD), composed of a T cell epitope from glycoprotein D (gD(8-23)) of herpes simplex virus (HSV) linked with a peptide sequence from beta-2-microglobulin (aa38-50), elicited protection against lethal…

Browse Items (7 total)